MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Abbott Laboratories

Suletud

SektorTervishoid

129.39 -0.45

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

128.02

Max

130.1

Põhinäitajad

By Trading Economics

Sissetulek

7.6B

9.2B

Müük

339M

11B

P/E

Sektori keskmine

17.001

57.333

Aktsiakasum

1.09

Dividenditootlus

1.8

Kasumimarginaal

84.099

Töötajad

114,000

EBITDA

82M

3B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+11.42% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.80%

2.63%

Järgmine dividendimakse kuupäev

15. mai 2025

Järgmine aktsia dividendi kuupäev (ex-date)

14. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

3B

225B

Eelmine avamishind

129.84

Eelmine sulgemishind

129.39

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Abbott Laboratories Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. apr 2025, 16:21 UTC

Tulu

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16. apr 2025, 12:14 UTC

Tulu

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

22. jaan 2025, 19:03 UTC

Tulu

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22. jaan 2025, 18:20 UTC

Tulu

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22. jaan 2025, 12:45 UTC

Tulu

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

16. apr 2025, 15:09 UTC

Market Talk

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16. apr 2025, 14:17 UTC

Tulu

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16. apr 2025, 11:34 UTC

Tulu

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16. apr 2025, 11:33 UTC

Tulu

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16. apr 2025, 11:32 UTC

Tulu

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16. apr 2025, 11:32 UTC

Tulu

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16. apr 2025, 11:31 UTC

Tulu

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16. apr 2025, 11:30 UTC

Tulu

Abbott Reaffirms Full-Yr Guidance

16. apr 2025, 11:30 UTC

Tulu

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16. apr 2025, 11:30 UTC

Tulu

Abbott Labs 1Q Sales $10.36B >ABT

16. apr 2025, 11:30 UTC

Tulu

Abbott Labs 1Q Net $1.33B >ABT

16. apr 2025, 11:30 UTC

Tulu

Abbott Labs 1Q EPS 76c >ABT

16. apr 2025, 11:30 UTC

Tulu

Abbott Labs 1Q Adj EPS $1.09 >ABT

16. apr 2025, 09:57 UTC

Kuumad aktsiad

Stocks to Watch: Nvidia, AMD, Heineken, ASML -- WSJ

1. veebr 2025, 18:14 UTC

Peamised uudised

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22. jaan 2025, 16:40 UTC

Peamised uudised
Tulu

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22. jaan 2025, 15:20 UTC

Tulu

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22. jaan 2025, 15:08 UTC

Tulu

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22. jaan 2025, 13:51 UTC

Tulu

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22. jaan 2025, 13:39 UTC

Peamised uudised
Tulu

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22. jaan 2025, 12:02 UTC

Tulu

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22. jaan 2025, 12:01 UTC

Tulu

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22. jaan 2025, 12:01 UTC

Tulu

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22. jaan 2025, 12:00 UTC

Tulu

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22. jaan 2025, 12:00 UTC

Tulu

Abbott Labs 4Q Net $9.23B >ABT

Võrdlus sarnastega

Hinnamuutus

Abbott Laboratories Prognoos

Hinnasiht

By TipRanks

11.42% tõus

12 kuu keskmine prognoos

Keskmine 144.15 USD  11.42%

Kõrge 159 USD

Madal 127 USD

Põhineb 21 Wall Streeti analüütiku instrumendi Abbott Laboratories 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

21 ratings

18

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

128.52 / 129.7Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.